John Huber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
John Huber has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Christopher E. Dandoy
Department of Pediatrics University of Cincinnati College of Medicine Cincinnati Ohio USA
6 shared publications - Jeffery J. Auletta
NMDP, Minneapolis, MN
4 shared publications Malika Kapadia
Dana‐Farber/Boston Children's Cancer and Blood Disorders Center Boston Massachusetts USA
4 shared publications- Priscila Badia
University of Cincinnati College of Medicine, Department of Pediatrics; Cincinnati Children's Hospital Medical Center, Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati, Ohio, USA
4 shared publications - Rachel Phelan
Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI
4 shared publications - Seth J. Rotz
Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland, Ohio
4 shared publications
Latest Publications
- 9 October 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (10) , e70493
Routine Central Venous Catheter Maintenance After Pediatric Hematopoietic Stem Cell Transplant: Direct Cost Observations From a Single Center and Practice Variation Across Engraft Centers
Background: Central venous catheters (CVCs) are essential during pediatric hematopoietic stem cell transplantation (HSCT), but prolonged retention exposes patients to infection, thrombosis, device complications, caregiver burden, and ongoing maintenance costs. Routine maintenance costs and variation in posttransplant CVC care have not been well characterized. Methods: We conducted a descriptive mixed‐methods study combining direct observation of CVC maintenance at Cincinnati Children's Hospital Medical Center with a cross‐sectional survey of Engraft Learning Health Network centers. Between January and March 2025, 15 dressing changes and 10 cap changes, predominantly on double‐lumen tunneled CVCs, were observed. Procedure time, staffing, supplies, and local labor and supply costs were evaluated using itemized micro‐costing. Fifteen respondents representing 10 Engraft centers reported routine dressing‐ and cap‐change practices. Results: Dressing‐change practices were consistent, with all centers reporting changes every 7 days or sooner when dressing integrity was compromised. Cap‐change intervals varied from daily to every 7 days. Dressing changes required a mean of 16.5 min and cost $55.25 in labor and supplies. Cap changes cost $24.08, and daily flushing cost $13.70. Estimated routine maintenance costs were $675–$728 per patient‐month. Conclusion: Routine CVC maintenance after pediatric HSCT is resource intensive and varies across centers. These findings support standardization of maintenance practices and timely CVC removal when central access is no longer clinically necessary.
- 9 October 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (10) , e70493
Routine Central Venous Catheter Maintenance After Pediatric Hematopoietic Stem Cell Transplant: Direct Cost Observations From a Single Center and Practice Variation Across Engraft Centers
Background: Central venous catheters (CVCs) are essential during pediatric hematopoietic stem cell transplantation (HSCT), but prolonged retention exposes patients to infection, thrombosis, device complications, caregiver burden, and ongoing maintenance costs. Routine maintenance costs and variation in posttransplant CVC care have not been well characterized. Methods: We conducted a descriptive mixed‐methods study combining direct observation of CVC maintenance at Cincinnati Children's Hospital Medical Center with a cross‐sectional survey of Engraft Learning Health Network centers. Between January and March 2025, 15 dressing changes and 10 cap changes, predominantly on double‐lumen tunneled CVCs, were observed. Procedure time, staffing, supplies, and local labor and supply costs were evaluated using itemized micro‐costing. Fifteen respondents representing 10 Engraft centers reported routine dressing‐ and cap‐change practices. Results: Dressing‐change practices were consistent, with all centers reporting changes every 7 days or sooner when dressing integrity was compromised. Cap‐change intervals varied from daily to every 7 days. Dressing changes required a mean of 16.5 min and cost $55.25 in labor and supplies. Cap changes cost $24.08, and daily flushing cost $13.70. Estimated routine maintenance costs were $675–$728 per patient‐month. Conclusion: Routine CVC maintenance after pediatric HSCT is resource intensive and varies across centers. These findings support standardization of maintenance practices and timely CVC removal when central access is no longer clinically necessary.
- Open Access
- 2 August 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1303.e1-1303.e12
Toward Standardized Screening for Chronic Graft-Versus-Host Disease: Insights from the Engraft Learning Network
- 2 August 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1303.e1-1303.e12
Open AccessToward Standardized Screening for Chronic Graft-Versus-Host Disease: Insights from the Engraft Learning Network
- 24 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (3) , e70001
Central Venous Catheter Removal After Hematopoietic Stem Cell Transplant: A Review and Perspective
Central venous catheters (CVCs) are a cornerstone of hematopoietic stem cell transplantation (HSCT), facilitating the delivery of chemotherapy, parenteral nutrition, medications, and blood products. Despite CVCs’ essential role, prolonged use can lead to complications such as increased risk of infection, thrombosis, mechanical issues, and psychosocial burden. However, the timing of CVC removal remains highly variable across institutions. Additionally, there are no standardized guidelines to balance the benefits of extended access against the risks of prolonged use. This narrative review examines the existing literature on CVC management post‐HSCT, highlighting key factors influencing the removal timing, such as patient characteristics, disease‐specific considerations, and institutional practices. The review emphasizes the urgent need for multi‐institutional research and standardized protocols to improve outcomes, reduce complications, and enhance the quality of care for HSCT patients.
- 24 November 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (3) , e70001
Central Venous Catheter Removal After Hematopoietic Stem Cell Transplant: A Review and Perspective
Central venous catheters (CVCs) are a cornerstone of hematopoietic stem cell transplantation (HSCT), facilitating the delivery of chemotherapy, parenteral nutrition, medications, and blood products. Despite CVCs’ essential role, prolonged use can lead to complications such as increased risk of infection, thrombosis, mechanical issues, and psychosocial burden. However, the timing of CVC removal remains highly variable across institutions. Additionally, there are no standardized guidelines to balance the benefits of extended access against the risks of prolonged use. This narrative review examines the existing literature on CVC management post‐HSCT, highlighting key factors influencing the removal timing, such as patient characteristics, disease‐specific considerations, and institutional practices. The review emphasizes the urgent need for multi‐institutional research and standardized protocols to improve outcomes, reduce complications, and enhance the quality of care for HSCT patients.
- Open Access
- 10 May 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (8) , 590.e1-590.e16
Multicenter Study on Caregiver Experiences in Pediatric Hematopoietic Stem Cell Transplantation: Part II. Treatment Challenges, Communication Barriers, and Caregiver-Driven Approaches to Mitigation
- 10 May 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (8) , 590.e1-590.e16
Open AccessMulticenter Study on Caregiver Experiences in Pediatric Hematopoietic Stem Cell Transplantation: Part II. Treatment Challenges, Communication Barriers, and Caregiver-Driven Approaches to Mitigation
- Open Access
- 30 December 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (3) , 123-134
Engraft: A Collaborative Learning Health Network for Enhanced Transplant and Cellular Therapy Outcomes
- 30 December 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (3) , 123-134
Open AccessEngraft: A Collaborative Learning Health Network for Enhanced Transplant and Cellular Therapy Outcomes
- Open Access
- 17 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31336
Invasive fungal infections are rare in pediatric and young adult autologous hematopoietic stem cell transplant patients
Background: Pediatric and young adult patients undergoing autologous hematopoietic stem cell transplant (auto‐HSCT) face a crucial, yet understudied, risk of invasive fungal infections (IFI), especially compared to allogeneic transplants. This gap underscores the need for research in pediatric patients undergoing auto‐HSCT. Our objective was to evaluate the incidence of IFI in pediatric and young adult patients during the first year after auto‐HSCT. Materials and methods: We conducted a single‐center retrospective analysis of 150 pediatric and young adult auto‐HSCT patients who underwent transplant from January 2013 to January 2023. We focused on IFI incidence within the first‐year post transplant, using the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria for IFI identification. Results: Among the 150 patients analyzed, with 240 unique transplant episodes, the primary indication was neuroblastoma (37.3%), and micafungin was extensively used for prophylaxis (82.7%). There was an absence of IFI from yeast and mold species, suggesting a low IFI risk in this cohort. The incidence of IFI in pediatric auto‐HSCT recipients receiving micafungin primary antifungal prophylaxis is rare. Conclusions: The findings advocate for further research to refine prophylaxis guidelines and highlight the need for individualized risk assessment to optimize post‐transplant care.
- 17 September 2024
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (12) , e31336
Open AccessInvasive fungal infections are rare in pediatric and young adult autologous hematopoietic stem cell transplant patients
Background: Pediatric and young adult patients undergoing autologous hematopoietic stem cell transplant (auto‐HSCT) face a crucial, yet understudied, risk of invasive fungal infections (IFI), especially compared to allogeneic transplants. This gap underscores the need for research in pediatric patients undergoing auto‐HSCT. Our objective was to evaluate the incidence of IFI in pediatric and young adult patients during the first year after auto‐HSCT. Materials and methods: We conducted a single‐center retrospective analysis of 150 pediatric and young adult auto‐HSCT patients who underwent transplant from January 2013 to January 2023. We focused on IFI incidence within the first‐year post transplant, using the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria for IFI identification. Results: Among the 150 patients analyzed, with 240 unique transplant episodes, the primary indication was neuroblastoma (37.3%), and micafungin was extensively used for prophylaxis (82.7%). There was an absence of IFI from yeast and mold species, suggesting a low IFI risk in this cohort. The incidence of IFI in pediatric auto‐HSCT recipients receiving micafungin primary antifungal prophylaxis is rare. Conclusions: The findings advocate for further research to refine prophylaxis guidelines and highlight the need for individualized risk assessment to optimize post‐transplant care.
- Open Access
- 26 June 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (9) , 539-547
Cell Therapy Informatics: Updates on the Integration of HCT/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safety, Research, and Data Interoperability
- 26 June 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (9) , 539-547
Open AccessCell Therapy Informatics: Updates on the Integration of HCT/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safety, Research, and Data Interoperability
- Open Access
- 12 September 2022
- Published by Wiley
What your educational video performance can tell you and why you should be looking.
Timely and relevant patient and family education can improve quality of life and outcomes for transplant families. Video’s popularity as an education medium has been increasing as the barriers to video production and consumption have decreased. To better understand the usage characteristics our education videos we obtained aggregated video performance statistics from YouTube for the Arabic, English, and Spanish versions of five division created bone marrow transplant educational videos. Comparing video views to patient transplants, considering patient language and transplant date, we found that views per patient by language were highest with Spanish language videos with a mean of 1.17 (range: 0.35 – 1.88), followed by English language videos at 0.96 (range: 0.52-2.41) and Arabic language videos trailed with a mean of 0.37 (range: 0.15-0.58) views per patient. Lifetime average watch percentages across all videos was 65.7% (range: 22.3% - 85.7%), with the non-English videos consistently having lower average viewing percentages. These data give important insights into our education delivery systems and the degree to which our content engages each of our patients and families.
- 12 September 2022
- Published by Wiley
Open AccessWhat your educational video performance can tell you and why you should be looking.
Timely and relevant patient and family education can improve quality of life and outcomes for transplant families. Video’s popularity as an education medium has been increasing as the barriers to video production and consumption have decreased. To better understand the usage characteristics our education videos we obtained aggregated video performance statistics from YouTube for the Arabic, English, and Spanish versions of five division created bone marrow transplant educational videos. Comparing video views to patient transplants, considering patient language and transplant date, we found that views per patient by language were highest with Spanish language videos with a mean of 1.17 (range: 0.35 – 1.88), followed by English language videos at 0.96 (range: 0.52-2.41) and Arabic language videos trailed with a mean of 0.37 (range: 0.15-0.58) views per patient. Lifetime average watch percentages across all videos was 65.7% (range: 22.3% - 85.7%), with the non-English videos consistently having lower average viewing percentages. These data give important insights into our education delivery systems and the degree to which our content engages each of our patients and families.
- Open Access
- 25 July 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (11) , 737-746
Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem
- 25 July 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (11) , 737-746
Open AccessSecondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem
- Open Access
- 10 February 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (5) , 233-241
Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes
- 10 February 2022
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 28 (5) , 233-241
Open AccessQuality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes